Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab′)2 components mediates reduced pulmonary inflammation in mice

References

1. Anderson, L. J., Bingham, P. & Hierholzer, J. C. ( 1988; ). Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 62, 4232–4238.
   [Google Scholar]
2. Brown, B. A., Comeau, R. D., Jones, P. L., Liberatore, F. A., Neacy, W. P., Sands, H. & Gallagher, B. M. ( 1987; ). Pharmokinetics of the monoclonal antibody B72.3 and its fragments labeled with either ¹²⁵I or ¹¹¹In. Cancer Res 47, 1149–1154.
   [Google Scholar]
3. Corbeil, S., Seguin, C. & Trudel, M. ( 1996; ). Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Vaccine 14, 521–525.[CrossRef]
   [Google Scholar]
4. Falsey, A. R., Cunningham, C. K., Barker, W. H., Kouides, R. W., Yuen, J. B., Menegus, M., Weiner, L. B., Bonville, C. A. & Betts, R. F. ( 1995; ). Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 172, 389–394.[CrossRef]
   [Google Scholar]
5. Fodha, I., Vabret, A., Bouslama, L., Leroux, M., Legrand, L., Dina, J., Gouarin, S., Petitjean, J., Dewar, J. & other authors ( 2008; ). Molecular diversity of the aminoterminal region of the G protein gene of human respiratory syncytial virus subgroup B. Pathol Biol (Paris) 56, 50–57.[CrossRef]
   [Google Scholar]
6. Hall, C. B., Walsh, E. E., Long, C. E. & Schnabel, K. C. ( 1991; ). Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163, 693–698.[CrossRef]
   [Google Scholar]
7. Harcourt, J. L., Brown, M. P., Anderson, L. J. & Tripp, R. A. ( 2003; ). CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice. Vaccine 21, 2964–2979.[CrossRef]
   [Google Scholar]
8. Harcourt, J. L., Karron, R. A. & Tripp, R. A. ( 2004; ). Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C–CX3CR1 binding and leukocyte chemotaxis. J Infect Dis 190, 1936–1940.[CrossRef]
   [Google Scholar]
9. Harcourt, J. L., Alvarex, R., Jones, L. P., Henderson, C., Anderson, L. J. & Tripp, R. A. ( 2006; ). Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1⁺ T cell responses. J Immunol 176, 1600–1608.[CrossRef]
   [Google Scholar]
10. Haynes, L. M., Tonkin, J., Anderson, L. J. & Tripp, R. A. ( 2002; ). Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol 76, 6873–6881.[CrossRef]
    [Google Scholar]
11. Haynes, L. M., Jones, L. P., Barskey, A., Anderson, L. J. & Tripp, R. A. ( 2003; ). Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C–CX3CR1 interaction and expression of substance P. J Virol 77, 9831–9844.[CrossRef]
    [Google Scholar]
12. Hirsch, R. L. ( 1982; ). The complement system: its importance in the host response to viral infection. Microbiol Rev 46, 71–85.
    [Google Scholar]
13. Mejías, A., Chávez-Beuno, S., Ríos, A. M., Saavedra-Lozano, J., Fonseca Aten, M., Hatfield, J., Kapur, P., Gómez, A. M., Jafri, H. S. & Ramilo, O. ( 2004; ). Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 48, 1811–1822.[CrossRef]
    [Google Scholar]
14. Mekseepralard, C., Toms, G. L. & Routledge, E. G. ( 2006; ). Protection of mice against human respiratory syncytial virus by wild-type and aglycosyl mouse–human chimeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein. J Gen Virol 87, 1267–1273.[CrossRef]
    [Google Scholar]
15. Panitch, H. B. ( 2001; ). Bronchiolitis in infants. Curr Opin Pediatr 13, 256–260.[CrossRef]
    [Google Scholar]
16. Plotnicky-Gilquin, H., Goetsch, L., Huss, T., Champion, T., Beck, A., Haeuw, J., Nguyen, T. N., Bonnefoy, J., Corvaïa, N. & Power, U. F. ( 1999; ). Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein. J Virol 73, 5637–5645.
    [Google Scholar]
17. Shay, D. K., Holman, R. C., Newman, R. D., Liu, L. L., Stout, J. W. & Anderson, L. J. ( 1999; ). Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 282, 1440–1446.[CrossRef]
    [Google Scholar]
18. Sullender, W. ( 1995; ). Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus. Virology 209, 70–79.[CrossRef]
    [Google Scholar]
19. Tripp, R. A. ( 2004; ). Pathogenesis of respiratory syncytial virus infection. Viral Immunol 17, 165–181.[CrossRef]
    [Google Scholar]
20. Tripp, R. A., Moore, D., Jones, L., Sullender, W., Winter, J. & Anderson, L. J. ( 1999; ). Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 73, 7099–7107.
    [Google Scholar]
21. Tripp, R. A., Jones, L. P., Haynes, L. M., Zheng, H., Murphy, P. M. & Anderson, L. J. ( 2001; ). CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2, 732–738.[CrossRef]
    [Google Scholar]
22. Varga, S. M. & Brachiale, T. J. ( 2002; ). RSV-induced immunopathology: dynamic interplay between the virus and host immune response. Virology 295, 203–207.[CrossRef]
    [Google Scholar]